Hikma, GSK end talks over potential Egypt, Tunisia assets deal
Potential buyout deal over
Reuters News - 11 Mar 2021
Hikma Pharmaceuticals PLC (HIK.DI)
Also known as: Hikma
56.71 USD 0.000.00%
Hikma Stock Price & Performance
Recommendation
-
Div Yield
0.882%
P/E (Last 12 Month)
0.0
Upside
-
Target Price (Mean)
-
Open
Data not available
Previous Close
56.71 USD
Turnover
Data not available
EPS
1.31 USD
Volume
0
Transactions
0
Market Cap
13.09B USD
IPO Date
01-Nov-2005
Analyst Estimates
| EPS | Revenue | |
|---|---|---|
| Mean Estimate |  | |
| Smart Estimate | | |
| Predicted Surprise | | |
| Mean Chg % | | |
Starmine Models
StarMine provides a suite of proprietary alpha-generating analytics and models spanning sectors, regions, and markets.
| Bullish | |
|---|---|
| Value Momentum | |
| Intrinsic Valuation | |
| Relative Valuation | |
| Credit Risk - Smart Ratios | |
| Credit Risk- Text Mining | |
| Bearish | |
|---|---|
| Price Momentum | |
About Hikma Pharmaceuticals PLC
Business Summary
Manufacturing and distribution of generic, branded and licensed pharmaceuticals; manufacturing of cosmetics, skin care, veterinary and plastic packaging products; provides biotechnology research services; ownership and operation of pharmacies and drug stores.
Country of Incorporation
Ownership Type
Established In
1978
Primary Sector
Stock Listing
| ID | Stock Type | Currency | Exchange | Symbol |
|---|---|---|---|---|
| HIK.DIFX | Ordinary | USD | Nasdaq Dubai | HIK |
Contact details
Primary address
Street: 13 Hanover SquareArea: Mayfair
P.O. Box: W1S 1HW
Country: United Kingdom
City: London
CONTACT
- Tel: +44 207-399-2760
- Tel: +962 6-580-2900
- Fax: +44 207-399-2761
- Email: business@hikma.com
- www.hikma.com
Related links
www.hikma-dz.comwww.west-ward.comwww.iprc.com.jowww.artioglobal.comwww.unimarkremedies.comwww.bedfordlabs.comwww.roxane.comRegion
LondonOwnership
Ownership
| Investor | Holding | No. of Shares | Last Update |
|---|---|---|---|
| | | |
| | | |
Holding Concentrations
| Investor | Holding | No. of Shares | Last Update |
|---|---|---|---|
| | | |
| | | |
Financials
Revenue
Net Income
Profit Margin
Total Assets
Total Liabilities
Debt to Assets
Operating
Investing
Financing
Executives
Mr Sigurdur Olafsson
Chief Executive Officer
Mr Khaled Al Nabilsi
Chief Financial Officer
Mr Bassam Wael Rushdi Kanaan
Chief Strategy and Corporate Development Officer
Board Members
HE Said Samih Taleb Darwazeh
Chairman
HE Mazen Samih Taleb Darwazeh
Vice Chairman
Mr Mohammed Ali Khaldoun Satea Al Husry
Director
Company information provided by Refinitiv
Refinitiv research team update company information from primary sources (company annual reports, press releases, company websites, corporate briefings, official statements/interviews) and reliable secondary sources (stock markets, reliable third party publications).
Zawya Coverage
UAE to suspend travel from India for 10 days starting April 25
Dubai's Azizi Developments claims first property sale to Israeli buyer
Saudi Arabia to set up $347mln tourism hub in Madinah KEC
World's busiest airports: Dubai falls off list; China dominates
Abu Dhabi Ports secures A+ credit rating from S&P
Thursday Outlook: Asia stocks join global equity rebound; oil slides on COVID-19 resurgence
Dollar loses bond yield support; gold nears $1,800 level
Stock Market Data
Powered By Knowledge Direct